(Q36539266)

14 August 2017

Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer (English)

1 reference

14 August 2017

1 reference

3

Aimery de Gramont

0 references

Jaffer Ajani

7

object named as

Jaffer A Ajani

1 reference

14 August 2017

Howard S Hochster

1

1 reference

14 August 2017

Daniel G Haller

2

1 reference

14 August 2017

Jordan D Berlin

4

1 reference

14 August 2017

Philip A Philip

5

1 reference

14 August 2017

Malcolm J Moore

6

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

14 August 2017

10

1 reference

inferred from page(s)

published in

Cancer

1 reference

14 August 2017

107

1 reference

14 August 2017

4

1 reference

14 August 2017

676-685

1 reference

14 August 2017

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

Systemic treatment of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

Complications of malignancy: case 3. Chronic lymphocytic leukemia presenting with panhypopituitarism

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

End points and United States Food and Drug Administration approval of oncology drugs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22036

7 January 2021

Identifiers

DOI

10.1002/CNCR.22036

1 reference

14 August 2017

1 reference